FindTrial
Sign In

STUDY TO IDENTIFY DISEASE FREE TIME AND OVERALL NUMBER OF PEOPLE SURVIVING IN BLOOD CANCER IN URBAN INDIA

A RETROSPECTIVE STUDY TO IDENTIFY PROGRESSION-FREE SURVIVAL PERIOD AND OVERALL SURVIVAL PERIOD IN MULTIPLE MYELOMA PATIENTS OF COMMUNITY ONCOLOGY IN URBAN INDIA

Status
Unknown
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/06/019646
Enrollment
101
Registered
2019-06-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D729- Disorder of white blood cells, unspecified

Interventions

Intervention1: NIL: NIL

Sponsors

Mumbai Oncocare Center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with a confirmed diagnosis of MM will be included

Exclusion criteria

Exclusion criteria: Patients not confirmed with MM will be excluded

Design outcomes

Primary

MeasureTime frame
To assess overall survival period To assess progression free survival periodTimepoint: Base line, End of the study 2 yrs—

Secondary

MeasureTime frame
To assess the safety profile as established by calculating the number of patient experiencing toxicity and analyssis of sevearity using CTCAE 5.0 criteria.Timepoint: Base line, End of the study 2 yrs—

Countries

India

Contacts

Public ContactSohal Pendse

Mumbai Oncocare Centre

ashjoshi44@mocindia.co.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026